Clinical effect of icotinib in the treatment of patients with advanced non-small cell lung cancer
Objective To analyze the clinical effect of icotinib in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 80 patients with advanced NSCLC admitted in our hospital from April 2019 to April 2022 were selected as the research objects.According to the random number table method,the patients were divided into control group(n=40,gefitinib)and study group(n=40,icotinib).The therapeutic effects of the two groups were compared.Results The disease control rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the miR-185-5p and miR-204-5p in the study group were higher than those in the control group,and the levels of lemur tyrosine kinase-3(LMTK-3)and POK erythroid myeloid ontogenic factor(Pokemon)were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the CD3+,CD4+,CD8+ and CD4+/CD8+ in the study group were better than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of complications between the two groups(P>0.05).The physical condition of the study group was better than that of the control group,and the difference was statistically significant(P<0.05).Conclusion The icotinib in the treatment of patients with advanced NSCLC has a obvious effect,it can improve the immune index and physical condition,better control the disease and improve the prognosis,which can be further promoted and applied in clinic.
万方数据
维普
